Close

Sierra Oncology (SRRA) Announces Initial Progress from Ongoing Phase 1 Clinical Trials of Chk1 Inhibitor SRA737

June 5, 2017 7:06 AM EDT Send to a Friend
Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login